Calidi Biotherapeutics, Inc.
CLDI
$1.36
$0.010.74%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.59M | 1.60M | 2.11M | 2.69M | 3.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.15M | 4.19M | 4.47M | 5.05M | 5.66M |
| Operating Income | -4.15M | -4.19M | -4.47M | -5.05M | -5.66M |
| Income Before Tax | -4.16M | -4.10M | -4.06M | -5.17M | -5.76M |
| Income Tax Expenses | 5.00K | 4.00K | -2.00K | 10.00K | 4.00K |
| Earnings from Continuing Operations | -4.16M | -4.11M | -4.06M | -5.18M | -5.76M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 3.00K | 32.00K | 46.00K |
| Net Income | -4.16M | -4.11M | -4.06M | -5.15M | -5.72M |
| EBIT | -4.15M | -4.19M | -4.47M | -5.05M | -5.66M |
| EBITDA | -3.71M | -3.76M | -3.14M | -4.94M | -5.26M |
| EPS Basic | -2.94 | -6.86 | -9.11 | -35.29 | -31.75 |
| Normalized Basic EPS | -1.83 | -3.98 | -6.04 | -10.43 | -19.73 |
| EPS Diluted | -2.94 | -6.86 | -9.11 | -35.29 | -31.75 |
| Normalized Diluted EPS | -1.83 | -3.98 | -6.04 | -10.43 | -19.73 |
| Average Basic Shares Outstanding | 1.42M | 644.30K | 445.10K | 306.70K | 180.00K |
| Average Diluted Shares Outstanding | 1.42M | 644.30K | 445.10K | 306.70K | 180.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |